Market research
NNNN Anbio Biotechnology Class A Ordinary Shares
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 299M
- P/E ratio
- 45.4
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- KYG0367B1059
- Market cap
- 299M
- P/E ratio
- 45.4
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- Not available
About
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the NNNN discussion.
No comments yet
Start a focused discussion about NNNN.